Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT05549297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
Lead sponsor
Immunocore Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
December 19, 2022
Completion date
July 31, 2028
Enrollment
540 (estimated)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma